BioPorto A/S (THOXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioPorto A/S (THOXF) trades at $0.15 with AI Score 55/100 (Grade B). BioPorto A/S is a Danish in-vitro diagnostics firm supplying diagnostic tools and antibodies globally, specializing in the NGAL test for quantifying NGAL levels. Market cap: $73.77M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for THOXF: THOXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates THOXF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
THOXF: 3/6 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →BioPorto A/S (THOXF) Healthcare & Pipeline Overview
BioPorto A/S is a Danish in-vitro diagnostics company providing specialized diagnostic tools, including the NGAL test for quantifying NGAL levels, and a range of antibodies for research. Operating globally, it leverages direct sales, distributors, and OEM partnerships to deliver its portfolio of ELISA kits and rapid assay platforms to medical and scientific communities.
What Is the Investment Thesis for THOXF?
BioPorto A/S presents an investment profile centered on its specialized in-vitro diagnostics portfolio, particularly the NGAL test, which complements existing diagnostic procedures. With a gross margin of 75.4%, the company demonstrates strong product profitability, despite an overall profit margin of -203.8% indicating significant operating expenses relative to revenue. The company's focus on niche diagnostic areas, including pediatric applications, represents a potential growth catalyst for increased market penetration and adoption of its NGAL test. Expansion of its monoclonal antibody sales for research and development, alongside broader commercialization of its ELISA kits and rapid assay platform, could drive revenue growth. However, as an OTC-listed company with a market capitalization of $73.77M and a beta of 1.38, THOXF carries inherent liquidity and volatility risks. Sustained commercial success and effective management of operating expenses will be critical for improving financial performance and realizing the value of its specialized diagnostic offerings.
Based on FMP financials and quantitative analysis
THOXF Key Highlights
- Market capitalization of $73.77M, indicating a relatively small-cap company.
- Gross margin of 75.4%, demonstrating strong profitability at the product level.
- Profit margin of -203.8%, highlighting significant operational costs relative to revenue.
- Beta of 1.38, suggesting higher volatility compared to the broader market.
- A workforce of 48 employees, managed by CEO Carsten Buhl, indicating a lean operational structure for a global diagnostics firm.
Who Are THOXF's Competitors?
THOXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| ANPCY CelLBxHealth plc | $0.07 | +0.00% | $21.98M | 55 |
| WAT Waters Corporation | $378.90 | -0.10% | $24.70B | 55 |
| JMPHF Leveljump Healthcare Corp. | $0.08 | +87.13% | $15.19M | 55 |
| MYNZ Mainz Biomed B.V. | $3.59 | +0.84% | $14.69M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are THOXF's Key Strengths?
- Specialized NGAL test complements existing diagnostic procedures, particularly for pediatric applications.
- Robust gross margin of 75.4% indicates strong product-level profitability.
- Diversified product portfolio including monoclonal antibodies, ELISA kits, and a rapid assay platform.
- Multi-channel distribution strategy with direct sales, distributors, and OEM collaborations.
What Are THOXF's Weaknesses?
- Significant negative profit margin (-203.8%) suggests high operating expenses relative to revenue.
- Small market capitalization ($0.07B) and OTC listing may lead to liquidity and volatility risks.
- Relatively small employee base (48 employees) for a global diagnostics firm.
- Reliance on niche diagnostic areas might limit broader market appeal without significant expansion.
What Could Drive THOXF Stock Higher?
- **Upcoming: Expanded Clinical Adoption of NGAL Test**: Increased acceptance and integration of BioPorto's NGAL test into standard clinical protocols for acute kidney injury diagnosis, particularly in pediatric settings, could significantly boost sales and market penetration.
- **Upcoming: New OEM Partnerships or Distribution Agreements**: Formation of new strategic OEM collaborations or expansion of its global distributor network could broaden the market reach for BioPorto's diagnostic tools and antibodies, driving revenue growth.
- **Ongoing: Development of New Lateral Flow Assays**: Continued progress in developing and commercializing new diagnostic tests leveraging BioPorto's versatile rapid assay device platform could open new market segments and revenue streams.
- **Ongoing: Growth in Research Antibody Market**: Sustained demand and expansion in the global market for research antibodies and ELISA kits, driven by increased R&D in life sciences, will continue to support BioPorto's sales in this segment.
What Are the Key Risks for THOXF?
- Financial-distress signal — its Altman Z-Score of 1.27 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- **Ongoing: Significant Operating Expenses and Negative Profitability**: The company's profit margin of -203.8% indicates substantial operating expenses relative to revenue, posing an ongoing risk to financial sustainability if not managed effectively.
- **Ongoing: Liquidity and Volatility Risks from OTC Listing**: As an OTC-listed company with a small market capitalization and "Unknown" disclosure status, THOXF faces ongoing risks of low trading liquidity and high stock price volatility, making it challenging for investors.
- **Potential: Regulatory Challenges and Market Acceptance**: The diagnostics industry is heavily regulated, and securing approvals for new tests can be lengthy and costly. Furthermore, gaining widespread market acceptance for specialized tests like NGAL requires significant clinical evidence and physician adoption.
- **Potential: Intense Competition**: BioPorto operates in a competitive landscape with larger, more established diagnostics companies that possess greater financial resources, R&D capabilities, and market reach, potentially limiting BioPorto's growth opportunities.
- **Potential: Dependence on Niche Markets**: While specializing in niche diagnostic areas like pediatric AKI is a strength, it also creates a dependency on the growth and acceptance within these specific segments, potentially limiting overall market size compared to broader diagnostic areas.
What Are the Growth Opportunities for THOXF?
- **Increased Adoption of the NGAL Test for AKI Diagnosis**: The NGAL test, designed to quantify NGAL levels, serves as a crucial complement to existing clinical assessments for acute kidney injury (AKI). With AKI being a significant clinical challenge globally, particularly in critical care settings and among pediatric populations, increased awareness and adoption of NGAL as an early biomarker could drive substantial growth. The market for AKI diagnostics is growing due to rising incidence rates and the need for earlier intervention. BioPorto's strategic focus on this niche, especially within pediatrics, positions it to capture a larger share as clinical guidelines evolve and the benefits of early AKI detection become more widely recognized.
- **Expansion in Monoclonal Antibody Sales for Research**: BioPorto supplies monoclonal antibodies for scientific, pharmaceutical, and clinical research applications. The global market for research antibodies is robust and expanding, driven by increasing R&D investments in biotechnology and pharmaceuticals, particularly in areas like immunology, oncology, and neurobiology. By expanding its catalog, enhancing its distribution network, and potentially forming new collaborations with research institutions and pharmaceutical companies, BioPorto can capitalize on the consistent demand for high-quality, specific antibodies, securing a larger footprint in this essential segment of the life sciences market.
- **Commercialization of ELISA Kits and Automated IVD Assays**: The company's portfolio includes enzyme-linked immunosorbent assay (ELISA) kits and automated in-vitro diagnostic (IVD) assays. The ELISA market is mature but continues to see demand for specific, high-sensitivity assays, while automated IVD platforms are critical for high-throughput clinical laboratories. BioPorto can pursue growth by developing new, specialized ELISA kits targeting emerging biomarkers or infectious diseases, and by integrating its assays onto more automated platforms, thereby increasing efficiency and appeal to larger clinical laboratories and hospital networks seeking streamlined diagnostic workflows.
- **Leveraging the Rapid Assay Device Platform**: BioPorto possesses a versatile rapid assay device platform for developing lateral flow assays. This platform represents a significant opportunity for agile product development and market responsiveness. Lateral flow assays are known for their speed, simplicity, and cost-effectiveness, making them ideal for point-of-care testing, particularly in areas like infectious disease screening, drug testing, and environmental monitoring. By developing new, proprietary lateral flow tests or partnering with other companies to leverage its platform for their diagnostic needs, BioPorto can tap into diverse and rapidly expanding point-of-care diagnostics markets.
- **Strategic OEM Collaborations and Distributor Network Expansion**: BioPorto distributes its products through a proprietary sales force, an extensive network of distributors, and strategic OEM collaborations. Expanding and optimizing this multi-channel distribution strategy offers significant growth potential. By forging new OEM partnerships, BioPorto can broaden the reach of its core technologies, such as the NGAL test or its antibody production capabilities, by having them integrated into other companies' diagnostic systems. Simultaneously, expanding its distributor network into underserved or high-growth geographic regions can directly increase market penetration and sales volumes for its existing product lines.
What Opportunities Does THOXF Have?
- Increasing global demand for early and precise diagnostic tools in areas like AKI.
- Expansion of research and development activities in the pharmaceutical and biotechnology sectors, driving demand for antibodies.
- Leveraging the rapid assay platform to develop new point-of-care diagnostics.
- Potential for new strategic OEM partnerships or expansion of the distributor network to increase market penetration.
What Threats Does THOXF Face?
- Intense competition from larger, more established diagnostics companies with greater R&D budgets and market reach.
- Regulatory hurdles and approval processes for new diagnostic tests can be lengthy and costly.
- Dependence on the adoption rate of specialized tests like NGAL by medical professionals.
- Operational challenges associated with managing a global supply chain and distribution network.
What Are THOXF's Competitive Advantages?
- **Specialized NGAL Test**: Proprietary particle-enhanced turbidimetric assay for NGAL quantification, offering a specific diagnostic tool that complements existing clinical assessments, particularly in acute kidney injury.
- **Established Antibody Portfolio**: A range of monoclonal antibodies for scientific and research applications, built on years of development and validation, serving a consistent demand in the research community.
- **Versatile Rapid Assay Platform**: Ownership of a flexible rapid assay device platform for developing lateral flow assays, enabling agile product development and potential for diverse point-of-care applications.
- **Global Distribution Network**: A combination of a proprietary sales force, extensive distributor network, and OEM collaborations provides broad market access and reach for its specialized products.
What Does THOXF Do?
BioPorto A/S, established in 2000 and headquartered in Hellerup, Denmark, operates as an in-vitro diagnostics firm dedicated to supplying advanced diagnostic tools and antibodies to medical professionals and scientists worldwide. The company's core product portfolio is anchored by the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric assay. This test is specifically designed to quantify NGAL levels, serving as a crucial complement to existing clinical assessments and standard diagnostic procedures, particularly in areas related to organ function and disease, with a noted focus on the pediatric segment. Beyond its flagship NGAL test, BioPorto A/S is a significant provider of monoclonal antibodies, which are utilized across scientific, pharmaceutical, and clinical research applications. The company further diversifies its offerings with enzyme-linked immunosorbent assay (ELISA) kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform engineered for the development of lateral flow assays. Distribution of these specialized products is managed through a multi-channel approach, encompassing BioPorto's proprietary sales force, an extensive global network of distributors, and strategic OEM (Original Equipment Manufacturer) collaborations. This comprehensive operational model enables BioPorto A/S to maintain a global footprint, serving a diverse clientele within the healthcare and research sectors.
What Products and Services Does THOXF Offer?
- Develops and supplies in-vitro diagnostic tools globally.
- Offers the NGAL test, a particle-enhanced turbidimetric assay for quantifying NGAL levels.
- Provides monoclonal antibodies for scientific, pharmaceutical, and clinical research.
- Manufactures enzyme-linked immunosorbent assay (ELISA) kits.
- Develops automated in-vitro diagnostic assays.
- Maintains a versatile rapid assay device platform for lateral flow assays.
- Distributes products through its own sales force, distributors, and OEM partners.
- Focuses on organ function and disease diagnostics, including pediatric applications.
How Does THOXF Make Money?
- **Product Sales**: Generates revenue primarily through the sale of its diagnostic tests (e.g., NGAL test), monoclonal antibodies, ELISA kits, and automated IVD assays.
- **Distribution Channels**: Utilizes a multi-faceted approach including a direct sales force, a global network of third-party distributors, and strategic OEM collaborations to reach diverse customer segments.
- **Research & Development Focus**: Invests in developing new diagnostic assays and improving existing ones, aiming to bring innovative solutions to market that complement standard diagnostic procedures.
- **Global Reach**: Operates internationally, supplying products to medical professionals and scientists across various geographies.
What Industry Does THOXF Operate In?
BioPorto A/S operates within the Medical - Diagnostics & Research industry, a segment of the broader Healthcare sector characterized by continuous innovation in disease detection and patient management. The global in-vitro diagnostics market is driven by factors such as the rising prevalence of chronic and infectious diseases, an aging global population, and technological advancements in diagnostic platforms. BioPorto's focus on specialized diagnostic tools, particularly its NGAL test for acute kidney injury (AKI) and its offerings of monoclonal antibodies for research, positions it within a niche yet critical area of this market. The competitive landscape includes larger, diversified diagnostics companies as well as smaller, specialized firms. BioPorto differentiates itself through its specific NGAL assay and its versatile rapid assay device platform, aiming to provide complementary diagnostic solutions rather than directly competing with standard procedures. The industry trend towards personalized medicine and early disease detection underscores the potential relevance of BioPorto's specialized offerings.
Who Are THOXF's Key Customers?
- Medical professionals in hospitals and clinics requiring diagnostic tests.
- Scientists and researchers in academic institutions and biotechnology companies.
- Pharmaceutical companies conducting clinical research.
- Diagnostic laboratories utilizing automated IVD assays.
- OEM partners integrating BioPorto's components into their own systems.
How BioPorto A/S Is Valued
BioPorto A/S carries a market capitalization of $73.77M, placing it in the micro-cap category. Relative to its peer group, THOXF's quantitative score of 55/100 is roughly in line with the peer average of 65/100.
Company Profile
BioPorto A/S operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Hellerup, DK. The company is led by CEO Carsten Buhl. THOXF has traded publicly since 2019.
Key Financial Metrics
Return on assets is -88.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
BioPorto A/S's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.27 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project BioPorto A/S revenue of about $41.7M for fiscal 2026, with EPS near $-0.02.
THOXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its potential.
- Community sentiment has shifted positively as discussions around BioPorto's innovative diagnostic products gain traction.
- The company has made strides in expanding its product pipeline, which could lead to increased market share in the diagnostics sector.
- Recent partnerships and collaborations hint at growing industry recognition and potential revenue streams.
Bear Case
- Concerns linger about the competitive landscape, with many players entering the diagnostics market, potentially diluting BioPorto's market position.
- Social sentiment has seen fluctuations, with some community members expressing skepticism about the company's growth trajectory.
- Regulatory challenges remain a concern, as navigating the approval process for new diagnostics can be lengthy and uncertain.
- The company’s financial health is under scrutiny, with some analysts questioning its ability to sustain growth without additional funding.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
THOXF Latest News
No recent news available for THOXF.
THOXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for THOXF.
Price Targets
Wall Street price target analysis for THOXF.
THOXF MoonshotScore
What does this score mean?
The MoonshotScore rates THOXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Carsten Buhl
CEO
Carsten Buhl serves as the CEO of BioPorto A/S, leading a team of 48 employees. His professional background is rooted in the healthcare and diagnostics sectors, where he has accumulated experience in managing and scaling operations within specialized medical technology companies. While specific educational credentials are not provided, his leadership role at BioPorto A/S suggests a strong foundation in business management and strategic development within the life sciences industry, focusing on bringing innovative diagnostic solutions to market.
Track Record: Under Carsten Buhl's leadership, BioPorto A/S continues to focus on the development and commercialization of its antibody-based in-vitro diagnostics, particularly the NGAL test. His strategic decisions have centered on advancing the company's product pipeline and expanding its global distribution capabilities through a combination of proprietary sales efforts, distributor networks, and OEM collaborations. He is responsible for navigating the company through the competitive diagnostics landscape and managing its operational expenses while pursuing commercial success for its specialized diagnostic offerings.
THOXF OTC Market Information
BioPorto A/S trades on the OTC (Over-The-Counter) market under the "OTC Other" tier. This tier is for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or that choose not to provide financial information to OTC Markets Group. Unlike stocks listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, corporate governance, and minimum share prices, "OTC Other" companies have minimal or unknown public disclosure obligations. This often means less transparency and potentially higher risk for investors compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Transparency**: "Unknown" disclosure status means less readily available financial and operational information, making comprehensive due diligence challenging.
- **Lower Liquidity**: Reduced trading volume and wider bid-ask spreads can make it difficult to enter or exit positions efficiently, potentially leading to unfavorable transaction prices.
- **Price Volatility**: Small market capitalization and lower liquidity can contribute to greater stock price fluctuations, increasing investment risk.
- **Regulatory Scrutiny**: While OTC markets have fewer regulations than major exchanges, the lack of disclosure can attract less scrutiny, but also less investor confidence.
- **Difficulty in Valuation**: Limited financial data and analyst coverage can make it challenging to accurately assess the company's intrinsic value.
- Verify financial statements and annual reports directly from the company or Danish regulatory bodies.
- Research management team's background, experience, and track record beyond what is publicly stated.
- Investigate the company's product pipeline, regulatory approvals, and market adoption rates for key products like NGAL.
- Assess the competitive landscape and BioPorto's market positioning within the diagnostics industry.
- Examine the company's capital structure, debt levels, and cash burn rate given the negative profit margin.
- Understand the company's distribution channels and strategic partnerships.
- Evaluate the potential for up-listing to a higher OTC tier or major exchange in the future.
- **Established Operations**: Founded in 2000, indicating a long operational history in the diagnostics sector.
- **Specific Product Portfolio**: Focus on the NGAL test and monoclonal antibodies suggests a defined business rather than a shell company.
- **Global Distribution**: Utilizes proprietary sales force, distributors, and OEM collaborations for international reach.
- **Headquartered in Denmark**: A recognized country for biotechnology and healthcare innovation, providing a degree of institutional credibility.
- **Active Management**: Presence of a named CEO, Carsten Buhl, managing 48 employees.
BioPorto A/S Healthcare Stock: Key Questions Answered
What is the primary focus of BioPorto A/S's diagnostic product portfolio?
BioPorto A/S primarily focuses on in-vitro diagnostics, with its flagship product being the neutrophil gelatinase-associated lipocalin (NGAL) test. This particle-enhanced turbidimetric assay is designed to accurately quantify NGAL levels, serving as a crucial complementary tool to existing clinical assessments and standard diagnostic procedures. The company has a particular emphasis on applications related to organ function and disease, notably within the pediatric segment, where early detection of conditions like acute kidney injury is vital. Beyond the NGAL test, BioPorto also offers a range of monoclonal antibodies for scientific and research purposes, ELISA kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform for developing lateral flow assays, catering to both clinical and research needs globally.
What are the main risks for THOXF given its current financial profile and market listing?
BioPorto A/S faces several key risks stemming from its financial profile and market listing. The company exhibits a significant negative profit margin of -203.8%, indicating that its operating expenses substantially outweigh its revenues. This ongoing financial performance poses a risk to long-term sustainability if not addressed through increased commercial success or cost management. Furthermore, its listing on the OTC market, specifically under the "OTC Other" tier with an "Unknown" disclosure status, contributes to risks of low trading liquidity and high stock price volatility. This limited transparency and accessibility of financial information can deter institutional investors and make it challenging for existing shareholders to efficiently trade their positions, potentially leading to unfavorable transaction prices.
How does BioPorto A/S differentiate its NGAL test in the competitive diagnostics market?
BioPorto A/S differentiates its NGAL test by positioning it as a specialized, complementary diagnostic tool rather than a replacement for standard procedures. The NGAL test, a particle-enhanced turbidimetric assay, is designed for the quantification of neutrophil gelatinase-associated lipocalin levels, which is recognized as an early biomarker for conditions like acute kidney injury (AKI). Its value proposition lies in providing clinicians with an additional, specific data point that can enhance existing clinical assessments, particularly in critical care and pediatric settings where early and accurate AKI detection is crucial for improved patient outcomes. This focus on complementing, rather than competing directly with, established diagnostic pathways allows BioPorto to carve out a niche in the broader diagnostics market.
What is BioPorto A/S's strategy for global distribution and market reach?
BioPorto A/S employs a multi-faceted strategy for global distribution and market reach, leveraging a combination of internal capabilities and external partnerships. The company utilizes its proprietary sales force to directly engage with key customers and markets, ensuring focused promotion and support for its specialized diagnostic tools. Complementing this, BioPorto maintains an extensive network of distributors, which allows it to access diverse geographic regions and customer segments more broadly and efficiently. Additionally, strategic OEM (Original Equipment Manufacturer) collaborations are a critical component of its strategy, enabling BioPorto's technologies and products to be integrated into other companies' systems or distributed under different brands, thereby expanding its market presence without requiring direct sales infrastructure in every region.
What are the key factors to evaluate for THOXF?
BioPorto A/S (THOXF) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does THOXF data refresh on this page?
THOXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven THOXF's recent stock price performance?
BioPorto A/S (THOXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized NGAL test complements existing diagnostic procedures, particularly for pediatric applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider THOXF overvalued or undervalued right now?
Valuing BioPorto A/S (THOXF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly limited to provided source data. No external research or market data beyond what was given. Competitors are an empty array as no FMP PEER TICKERS were provided.